Physician profile
Krishnendu Bhadra
NPI 1093850745
$494,413.60
in general payments reported to CMS, 2019-2025
22 companies · $132K in 2025
The $132K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49K · 2020: $11K · 2021: $18K · 2022: $56K · 2023: $51K · 2024: $177K · 2025: $132K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $268K · Travel and Lodging: $42K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $23K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $7,585 · Honoraria: $4,500 · Education: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $267,967.78 |
| Travel and Lodging | $41,946.19 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $23,000.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,982.80 |
| Food and Beverage | $7,585.38 |
| Honoraria | $4,500.00 |
| Education | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noah Medical Corporation | $289,788.54 | 2023-2025 | Galaxy |
| Intuitive Surgical, INC. | $58,275.55 | 2019-2025 | Da Vinci Surgical System |
| Serpex Medical INC | $46,898.83 | 2024-2025 | |
| Covidien Lp | $34,889.40 | 2019-2020 | |
| Astrazeneca Uk Limited | $18,877.33 | 2022-2024 | Imfinzi |
| Siemens Medical Solutions USA, INC. | $17,779.83 | 2021-2023 | Artis Zeego |
| Ethicon Endo-Surgery INC. | $6,326.07 | 2022 | |
| Medtronic, INC. | $5,605.97 | 2021-2024 | Illumisite |
| Erbe USA INC | $4,538.58 | 2022-2023 | Erbe Vio Apc Cryo, Erbe Apc Vio Cryo |
| Janssen Scientific Affairs, LLC | $4,450.21 | 2025 | |
| Galvanize Therapeutics, INC | $2,332.26 | 2025 | Aliya System |
| Ethicon INC. | $2,256.03 | 2021-2023 | Monarch Platform |
| Pulmonx Corporation | $1,505.70 | 2022-2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Olympus America INC. | $318.17 | 2019-2022 | |
| Ge Healthcare | $153.66 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Body Vision Medical INC. | $147.19 | 2023 | Lungvision |
| Inari Medical, INC. | $87.17 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Insmed, INC. | $51.49 | 2022-2023 | Arikayce |
| Philips North America LLC | $50.00 | 2025 | Azurion 7 M20 |
| 4dmedical USA INC | $33.01 | 2024 | Ct Lvas |
| Pfizer INC. | $29.80 | 2019-2022 | |
| United Therapeutics Corporation | $18.81 | 2023 | Tyvaso |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishnendu Bhadra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.